Stock Evaluator: Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals, Inc. CTXR

$0.51 -0.01 -1.56%
November 18, 2026 4:00:00 PM EST November 10, 2021 Volume: 65,403
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Commentary & Analysis


Financial Summary

Share Statistics CTXR Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $14.0 $421.0 9%
Shares Out (Mil) 26.2 46.5 34%
Institutional Ownership 71.9% 82.0% 43%
Float (Mil) 27.0 48.3 33%
Beta 0.99 0.68 59%
Avg Daily Volume (000s) 247 348 47%
Price Change
(52-week)
(45.4%) 52.0% 22%
Growth CTXR Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.6% na
Net Income (5yr) (16.4%) (1.6%) 24%
EPS (5yr) 21.3% 15.1% 71
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) (52.7%) (15.1%) 6%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 1 1 1
Current EPS ($0.410) ($2.030) ($1.440)
Month Ago EPS ($0.410) ($2.030) ($1.440)
# Rev Up 0 1 1
# Rev Down 1 0 0
Three Months Ago EPS ($0.410) ($2.030) ($1.440)
Year/Year Chg 20.9% (40.0%) (80.2%)
Financials CTXR Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $7 $289 7%
Net Income (TTM) (Mil) ($46) ($11) 16%
EPS (TTM) ($2.122) ($0.600) 14%
Operating Cash Flow (TTM) (Mil) ($35) ($7) 12%
Net Cash Flow (TTM) (Mil) $11 $1 59%
Long-Term Debt (Q1) (Mil) $7 $4 26%
Enterprise Value (Q1) (Mil) $16 $331 11%
Valuation CTXR Industry
Median
Percentile
(All Stocks)
P/B 0.21 2.27 4%
P/E na 24.1 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.2 na
Ratios CTXR Industry
Median
Percentile
(All Stocks)
Gross Margin 77.3% 69.4% 87%
Net Margin (651.3%) 3.9% 1%
ROA (34.3%) (23.8%) 15%
ROE (70.3%) (24.7%) 12%
Liabilities to Assets 46.6% 32.0% 38%
F-Score 3 3 18%

Citius Pharmaceuticals, Inc. did not pass any screens on 11/18/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors